CERo TherapeuticsCERO
About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Employees: 8
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
350% more capital invested
Capital invested by funds: $528K [Q1] → $2.38M (+$1.85M) [Q2]
24.03% more ownership
Funds ownership: 23.86% [Q1] → 47.89% (+24.03%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
40% less funds holding
Funds holding: 15 [Q1] → 9 (-6) [Q2]
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert | 290%upside $30 | Buy Maintained | 4 Aug 2025 |
Financial journalist opinion









